MX2009003750A - Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular. - Google Patents
Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.Info
- Publication number
- MX2009003750A MX2009003750A MX2009003750A MX2009003750A MX2009003750A MX 2009003750 A MX2009003750 A MX 2009003750A MX 2009003750 A MX2009003750 A MX 2009003750A MX 2009003750 A MX2009003750 A MX 2009003750A MX 2009003750 A MX2009003750 A MX 2009003750A
- Authority
- MX
- Mexico
- Prior art keywords
- intraocular pressure
- a3ar
- antagonist
- adenosine
- species
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85017506P | 2006-10-06 | 2006-10-06 | |
| PCT/US2007/021409 WO2008045330A2 (en) | 2006-10-06 | 2007-10-05 | Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009003750A true MX2009003750A (es) | 2009-06-18 |
Family
ID=39283379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009003750A MX2009003750A (es) | 2006-10-06 | 2007-10-05 | Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20090258836A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2076267A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010505848A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007307157A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0715318A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2665616A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009003750A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008045330A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013516495A (ja) | 2010-01-11 | 2013-05-13 | イノテック ファーマシューティカルズ コーポレイション | 眼圧を低下させる組合せ、キット、および方法 |
| JP2013523739A (ja) * | 2010-03-26 | 2013-06-17 | イノテック ファーマシューティカルズ コーポレイション | N6−シクロペンチルアデノシン(cpa)、cpa誘導体またはそれらのプロドラッグを用いてヒトにおける眼内圧を低下させる方法 |
| SMT201700377T1 (it) | 2012-01-26 | 2017-09-07 | Inotek Pharmaceuticals Corp | Polimorfi anidri di (2r,3s,4r,5r)-5-(6-(ciclopentilammino)-9h-purin-9-il)-3,4- diidrossitetraidrofuran-2-il)}metil nitrato e processi di sua preparazione |
| NZ630759A (en) | 2013-03-15 | 2017-07-28 | Inotek Pharmaceuticals Corp | Ophthalmic formulations comprising an a1 agonist |
| ES2578363B1 (es) | 2015-01-22 | 2017-01-31 | Palobiofarma, S.L. | Moduladores de los receptores A3 de adenosina |
| US10196396B2 (en) | 2016-01-14 | 2019-02-05 | Handok Inc. | Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof |
| ES2676535B1 (es) | 2017-01-20 | 2019-04-29 | Palobiofarma Sl | Moduladores de los receptores a3 de adenosina |
| KR101805400B1 (ko) * | 2017-03-21 | 2017-12-07 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 녹내장 예방 및 치료용 약학적 조성물 |
| CN109666053A (zh) * | 2017-10-16 | 2019-04-23 | 张家口华健致远生物科技有限公司 | 一种a3腺苷受体激动剂及其用途 |
| KR102007640B1 (ko) * | 2017-11-29 | 2019-08-07 | 퓨쳐메디신 주식회사 | 아데노신 유도체를 포함하는 망막 질환 또는 시신경 질환 예방 및 치료용 약학적 조성물 |
| US11395597B2 (en) * | 2018-06-26 | 2022-07-26 | General Electric Company | System and method for evaluating blood flow in a vessel |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4431638B2 (ja) * | 1996-01-29 | 2010-03-17 | アメリカ合衆国 | ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途 |
| EP1096975B1 (en) * | 1998-07-16 | 2005-03-16 | The Trustees Of The University Of Pennsylvania | Use of a3 adenosine receptor antagonists in the manufacture of a medicament for reducing intraocular pressure |
| IL133680A0 (en) * | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
-
2007
- 2007-10-05 BR BRPI0715318-0A patent/BRPI0715318A2/pt not_active IP Right Cessation
- 2007-10-05 AU AU2007307157A patent/AU2007307157A1/en not_active Abandoned
- 2007-10-05 WO PCT/US2007/021409 patent/WO2008045330A2/en not_active Ceased
- 2007-10-05 EP EP07852549.0A patent/EP2076267A4/en not_active Withdrawn
- 2007-10-05 JP JP2009531464A patent/JP2010505848A/ja active Pending
- 2007-10-05 MX MX2009003750A patent/MX2009003750A/es active IP Right Grant
- 2007-10-05 CA CA002665616A patent/CA2665616A1/en not_active Abandoned
-
2009
- 2009-04-06 US US12/419,062 patent/US20090258836A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0715318A2 (pt) | 2013-07-16 |
| EP2076267A4 (en) | 2013-07-31 |
| US20090258836A1 (en) | 2009-10-15 |
| AU2007307157A1 (en) | 2008-04-17 |
| WO2008045330A2 (en) | 2008-04-17 |
| JP2010505848A (ja) | 2010-02-25 |
| EP2076267A2 (en) | 2009-07-08 |
| WO2008045330A3 (en) | 2008-06-26 |
| CA2665616A1 (en) | 2008-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008045330A3 (en) | Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure | |
| MY208749A (en) | Biligand drug conjugates and uses thereof | |
| EP2524693B1 (en) | Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability | |
| TW200806318A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
| EP2533785B1 (en) | Treatment of loss of sense of touch with saxitoxin derivatives | |
| IL172082A0 (en) | Foamable pharmaceutical compositions and methods for treating a disorder | |
| JP2009501797A5 (cg-RX-API-DMAC7.html) | ||
| MX2010013766A (es) | Rasagilina para modificacion de enfermedad de parkinson. | |
| JP6466504B2 (ja) | 長時間の眼圧低下効果を有するアルファ−2アドレナリンアゴニスト | |
| EA024042B1 (ru) | Способ снижения внутриглазного давления у людей | |
| JP2010505848A5 (cg-RX-API-DMAC7.html) | ||
| AU2014232881A1 (en) | Neosaxitoxin combination formulations for prolonged local anesthesia | |
| WO2000012098A1 (en) | Medicinal compositions for treating eye diseases | |
| BR112018014467A2 (en) | drug-antibody synergism technology for disease treatment | |
| WO2009022897A3 (es) | Composición farmacéutica sinergica, útil para inhibir la neovascularización (angiogénesis) corneal y retinal y de otros órganos en un humano o animal | |
| EP2671589A1 (en) | Medicinal agent for prevention or treatment of diseases associated with intraocular neovascularization and/or intraocular vascular hyperpermeability | |
| CN108261390A (zh) | 一种布林佐胺溴莫尼定滴眼液及其制备方法 | |
| NO20092764L (no) | Isosorbid mononitrat derivater for behandling av okular hypertensjon | |
| US20170368072A1 (en) | Par-4 agonists for the treatment of cancer | |
| EP1297849B1 (en) | Remedial agent for optic nerve diseases | |
| WO2007075720A8 (en) | Topical mecamylamine formulations for ocular administration and uses thereof | |
| JP2009519962A5 (cg-RX-API-DMAC7.html) | ||
| EP1410808A1 (en) | Optic nerve protecting agents containing alpha 1 receptor blocker as the active ingredient | |
| KR20120112162A (ko) | 황반변성 예방 또는 치료용 약학 조성물 | |
| US20110281813A1 (en) | Method of treating c-kit positive relapsed acute myeloid leukemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |